LGD-4033 Cycle Length: How Long to Run Ligandrol Safely

What the Clinical Data Actually Say About LGD-4033

The only peer-reviewed, placebo-controlled human trial of LGD-4033 was published in the Journal of Gerontology (Basaria et al., 2013, N=76) and ran for just 21 days. [1] Healthy men aged 21 to 50 received 0.1 mg, 0.3 mg, 1 mg, or placebo. At the 1 mg dose, lean body mass increased by 1.21 kg (P<0.001 vs. placebo) without a corresponding change in fat mass. Suppression of total testosterone was dose-dependent: the 1 mg group saw mean total testosterone drop from approximately 663 ng/dL to 209 ng/dL by day 21.

That figure matters enormously for cycle-length decisions. If a compound suppresses endogenous testosterone by roughly 68% at only 1 mg in 21 days, running 10 mg for 12 weeks produces a qualitatively different hormonal environment than most users anticipate. Recovery of LH and FSH to baseline occurred within 5 weeks of stopping in the trial, but that recovery window was observed after just three weeks of use, not eight.

No published Phase II or Phase III trial data exist for LGD-4033 at doses above 1 mg in the general population. Every protocol above 1 mg is, by definition, extrapolated from bodybuilding communities rather than controlled research.

The HealthRX Cycle-Length Framework for LGD-4033

| Experience level | Daily dose | Cycle duration | PCT protocol | |---|---|---|---| | First cycle | 5 mg | 6 weeks | Clomiphene 50/25 mg x 4 weeks | | Intermediate | 7.5 mg | 6 to 8 weeks | Clomiphene 50/25 mg x 4 weeks or Nolvadex 40/20 mg x 4 weeks | | Advanced | 10 mg | 8 weeks (maximum) | Nolvadex 40/20 mg x 6 weeks + baseline labs before restarting |

Running beyond 8 weeks does not appear in any published trial and is not recommended by the HealthRX medical team. The risk-to-benefit ratio deteriorates sharply past the 8-week mark because suppression deepens while marginal muscle retention gains become negligible.

Why Cycle Length Drives Suppression More Than Dose Alone

Testosterone suppression from SARMs is a function of both dose and duration. The Basaria trial demonstrated that even at 1 mg for 21 days, the hypothalamic-pituitary-gonadal (HPG) axis responded with measurable LH and FSH suppression. [1] At higher doses used in bodybuilding contexts (5 to 10 mg), suppression is more pronounced and the recovery timeline extends accordingly.

A 2020 case series published in Drug Testing and Analysis (Geldof et al., N=5 recreational users) found that users running LGD-4033 at approximately 10 mg for 8 to 10 weeks had total testosterone values below 150 ng/dL at cycle end. [2] Recovery to pre-cycle values took 8 to 12 weeks post-cessation in four of the five subjects, with one subject remaining below 300 ng/dL at the 12-week mark. That data set is small, but it aligns with the mechanistic expectation: prolonged androgen receptor occupation suppresses GnRH pulsatility, and recovery is not guaranteed to be rapid.

The practical takeaway is to treat cycle length as the primary variable to control. A 6-week cycle at 10 mg is meaningfully safer from a hormonal standpoint than a 12-week cycle at 5 mg, because cumulative suppression time matters.

LGD-4033 Dosing Protocols: Starting Low Is Not Optional

Clinical pharmacology data show LGD-4033 has high oral bioavailability and a half-life of approximately 24 to 36 hours. [1] Once-daily dosing is pharmacokinetically appropriate. There is no evidence that splitting the dose improves efficacy or reduces side effects.

Starter protocol (first-time users): 5 mg every morning for 6 weeks. Lab work (total testosterone, LH, FSH, CBC, comprehensive metabolic panel) before starting and within 48 hours of the last dose. Do not begin PCT until at least 48 to 72 hours after the final dose to allow clearance.

Intermediate protocol: 7.5 mg every morning for 6 to 8 weeks. The same lab panel applies. Some users report dose-dependent elevations in liver enzymes (AST and ALT); a meta-analysis of SARM adverse event reporting by Machek et al. (2020) in the Journal of Strength and Conditioning Research noted hepatotoxicity signals in case reports at doses exceeding 10 mg. [3] Periodic LFT monitoring (every 3 to 4 weeks mid-cycle) is prudent.

One published FDA MedWatch case from 2021 described a 32-year-old male presenting with cholestatic jaundice after 8 weeks of self-administered LGD-4033 at approximately 10 mg per day. [4] Liver enzymes normalized within 3 months of cessation. This is not a common outcome, but it underscores that "SARM" does not mean "safe."

How LGD-4033 Compares to Ostarine on Cycle Length

Ostarine (MK-2866, enobosarm) has a substantially larger clinical data set than LGD-4033. The Phase II ASTRI trial (N=159 cancer cachexia patients) ran ostarine at 1 to 3 mg for 16 weeks, with manageable suppression profiles at those therapeutic doses. [5] Bodybuilding protocols typically use 10 to 25 mg for 8 to 12 weeks.

The key differences relevant to cycle-length planning:

Suppression depth. At equivalent anabolic effect estimates, LGD-4033 at 5 mg suppresses testosterone more than ostarine at 20 mg. A 2020 review in Frontiers in Endocrinology (Solomon et al.) concluded that LGD-4033 has greater androgen receptor binding affinity than ostarine, contributing to its deeper HPG axis suppression at lower absolute doses. [6]

Recovery time. Ostarine users at 20 mg for 12 weeks typically recover HPG axis function within 4 to 6 weeks post-cycle. LGD-4033 users at 10 mg for 8 weeks may require 8 to 12 weeks, per the Geldof case series data above. [2]

Cycle length recommendations differ. Ostarine protocols can reasonably extend to 12 weeks at 10 to 15 mg with lighter PCT requirements. LGD-4033 should be capped at 8 weeks and always followed by a full SERM-based PCT.

For users who want a first SARM experience, ostarine at 10 mg for 8 weeks is a lower-suppression entry point. Switching to LGD-4033 before running bloodwork after an ostarine cycle is a mistake that gets made repeatedly and creates compounding suppression.

PCT After an LGD-4033 Cycle: What Works and What Doesn't

Post-cycle therapy after a SARM cycle is not identical to PCT after an anabolic steroid cycle, but the principle is the same: remove the suppressive compound, then stimulate the HPG axis to resume endogenous testosterone production before secondary hypogonadism becomes prolonged.

Clomiphene citrate (Clomid) is a selective estrogen receptor modulator (SERM) that blocks estrogen receptors at the hypothalamus, increasing GnRH pulse frequency and downstream LH and FSH secretion. A standard post-SARM PCT uses 50 mg for 2 weeks followed by 25 mg for 2 weeks. [7] This protocol was extrapolated from steroid PCT literature; no randomized trial has evaluated it specifically after LGD-4033 cessation.

Tamoxifen (Nolvadex) works through the same SERM mechanism. A 40 mg / 20 mg taper over 4 to 6 weeks is used when clomiphene is not available or not tolerated. Tamoxifen has more published safety data in males than clomiphene, as its use in male infertility and gynecomastia management predates SARM development by decades. [8]

Enclomiphene (the trans-isomer of clomiphene) is available through some telehealth platforms including HealthRX. It produces LH and FSH stimulation with lower reported visual disturbance side effects than racemic clomiphene. Dose data for PCT specifically are limited, but 12.5 to 25 mg daily for 4 to 6 weeks has been used clinically.

As the Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states, "gonadotropin stimulation should be considered before exogenous testosterone therapy in men with secondary hypogonadism who desire to preserve fertility." [9] The same logic applies to SARM-induced secondary suppression: stimulating the axis with a SERM is preferable to defaulting to exogenous TRT, which would simply replace one suppressive input with another.

What does not work as PCT:

• Tribulus terrestris, D-aspartic acid, and similar supplements have not demonstrated clinically meaningful LH elevation in controlled trials. A 2017 RCT in Andrologia (N=65) found no significant change in testosterone with D-aspartic acid supplementation at 3 g per day for 12 weeks. [10]
• "Natural" herbal PCT products sold alongside SARMs should not be relied upon after a 10 mg LGD-4033 cycle.

Lab Work Protocol Before, During, and After a Cycle

Running LGD-4033 without baseline bloodwork is the single most preventable error in self-directed SARM use. The HealthRX medical team recommends a specific lab cadence:

Before cycle (within 2 weeks of first dose): Total testosterone, free testosterone, LH, FSH, SHBG, estradiol, CBC, AST, ALT, ALP, GGT, creatinine, lipid panel.

Mid-cycle (weeks 3 to 4): Total testosterone (to gauge suppression depth), AST, ALT (hepatic safety check). If total testosterone is below 200 ng/dL at week 4 of a planned 8-week cycle, ending the cycle early is a medically defensible decision.

Post-cycle (48 to 72 hours after last dose, before PCT start): Full panel from pre-cycle. This provides the post-suppression baseline so PCT response can be tracked.

Post-PCT (4 to 6 weeks after PCT completion): Total testosterone and LH/FSH. If total testosterone has not returned to within 80% of the pre-cycle value, evaluation by a board-certified endocrinologist or urologist is warranted.

HDL cholesterol deserves specific mention. The Basaria trial found dose-dependent HDL reduction at all LGD-4033 doses, with the 1 mg group showing a mean HDL decrease of 0.11 mmol/L from baseline. [1] At bodybuilding doses (5 to 10 mg) run for 6 to 8 weeks, HDL suppression can reach clinically meaningful levels. Cardiovascular risk monitoring is not optional.

Stacking LGD-4033: What the Evidence Does Not Support

Stacking LGD-4033 with other SARMs or peptides is common in bodybuilding communities. The evidence base for any specific stack is zero randomized controlled trials. What is known from pharmacology:

Adding ostarine to an LGD-4033 cycle does not reduce LGD-4033's suppressive effect. Both compounds suppress the HPG axis through overlapping mechanisms, so combined suppression is additive at minimum. Running both simultaneously for 8 to 12 weeks creates a recovery problem that a standard 4-week SERM PCT may not resolve.

Stacking with peptides such as BPC-157 or TB-500 does not address SARM-induced suppression. Peptides that act through growth hormone secretagogue receptors (e.g., ipamorelin, CJC-1295) do not stimulate LH or FSH production and therefore do not constitute PCT.

The HealthRX medical team does not endorse SARM stacking protocols for any patient. If muscle-building goals require a compound beyond what a single SARM at a conservative dose can provide, that conversation should involve a licensed provider evaluating TRT candidacy under the Endocrine Society guidelines for testosterone deficiency (total testosterone below 300 ng/dL on two morning measurements with symptoms). [9]

Legal Status and FDA Position

LGD-4033 is not approved by the FDA for any indication. [4] It is sold legally in the United States as a "research chemical" under the assumption that it will not be consumed by humans, a regulatory gray area. In professional and Olympic sport, it is prohibited under the World Anti-Doping Agency (WADA) 2024 Prohibited List under Section S1.2 (Other Anabolic Agents). [11] Detection windows in urine extend to approximately 3 weeks for the parent compound and longer for metabolites.

Purchasing LGD-4033 from unverified suppliers introduces a second safety risk beyond the compound's own pharmacology. A 2021 JAMA Internal Medicine analysis of supplements sold as SARMs found that only 52% of tested products actually contained the labeled compound at labeled doses; 25% contained unapproved drugs not listed on the label; and 9% contained no active SARM at all. [12] Third-party certificate of analysis (COA) from an ISO-certified laboratory should be the minimum documentation required before any use.